Coronavirus: The Tide Is Coming for Medicinal Cannabis
Bloomberg Creative / Bloomberg Creative Photos / Getty Images
By Zulfikar Abbany
The search for a vaccine for the new coronavirus, SARS-CoV-2, or indeed a medicinal drug to cure it, has taken researchers down both traditional and less traditional avenues.
They have looked at existing drug candidates, such as remdesivir, which was original developed to treat Ebola. In Germany, the first clinical trials for a coronavirus vaccine are based on a candidate developed for cancer immunology.
There's a study out of France that suggests nicotine — typically ingested via the often-lethal pastime of smoking — may protect people against the novel coronavirus, itself a potentially fatal lung infection.
And, now, preliminary research is emerging out of Canada that certain strains of the psychoactive drug cannabis may also increase resistance to the coronavirus. If the study, which is not yet peer reviewed, can be verified, it would appear that cannabis works in a similar way to nicotine.
"The results on COVID-19 came from our studies on arthritis, Crohn's disease, cancer and others," said Dr. Igor Kovalchuck, a professor of Biological Sciences at the University of Lethbridge, in an email to DW.
As with the research into nicotine's effect on the coronavirus, it is thought that some strains of cannabis reduce the virus' ability to enter the lungs, where it takes hold, reproduces and spreads.
In a paper on preprints.org, where scientists can publish non-peer-reviewed results, Kovalchuck and colleagues write that their specially developed strains of cannabis effectively stop the virus from entering the human body.
The study is one of many papers globally that have been shared on preprint websites, including preprints.org, in a bid to disseminate preliminary findings into potential COVID-19 treatments that have yet to undergo rigorous peer review.
The coronavirus needs a "receptor" to enter a human host. That receptor is known as an "angiotensin-converting enzyme II," or ACE2.
ACE2 is found in lung tissue, in oral and nasal mucus, in the kidneys, testes, and gastrointestinal tracts, they write.
And the theory is that by modulating ACE2 levels in those "gateways" to the human host, it may be possible to lower our susceptibility, or vulnerability, to the virus. It could basically reduce our risk of infection.
"If there's no ACE2 on tissues, the virus will not enter," said Kovalchuck.
No Common or Garden Cannabis
Some in the science community say medicinal cannabis may help to treat a range of conditions from nausea to dementia. But medicinal cannabis is not the same as what you might call recreational cannabis.
Those more "common or garden varieties" of cannabis — or street cannabis — are known for their Tetrahydrocannabinol (THC) content. That's the main psychoactive agent in the drug.
The Alberta-based researchers, meanwhile, have focused on strains of the plant, Cannabis sativa, that are high in an anti-inflammatory cannabinoid, cannabidiol (CBD) — one of the other main chemicals in cannabis, aside from THC.
They have developed more than 800 new Cannabis sativa variants, with high levels of CBD, and identified 13 extracts which they say modulate ACE2 levels in those humans gateways.
"Our varieties are high in CBD, or balanced CBD/THC, because you can give a higher dose and people will not be impaired due to the psychoactive properties of THC," said Kovalchuck.
Low Funding, Low Knowledge
Kovalchuck also heads a company called Inplanta BioTechnology, with Dr. Darryl Hudson, who has a PHD from the University of Guelph — another Canadian institute where research is ongoing into the use of cannabinoids in medicine.
But funding for cannabinoid research is "still hard," he said. And that's the case in other countries, too.
Some researchers in the UK say that may be because there are misconceptions among the general public and politicians about medicinal cannabis, perhaps even a fear that people will become addicted or try to self-medicate, using just any old form of cannabis they can find.
Those researchers say themselves that it is vital to be clear about the information and to avoid sensationalism.
"Researchers have to be particularly careful when disseminating their results given the socio-political volatility of medicinal cannabis use," said Chris Albertyn, a Research Portfolio Lead at King's College London, and an expert on cannabinoids and dementia.
The best way to get through that, says Albertyn, is to implement open, transparent research methods.
"In this instance, the current research from Canada has just unveiled a potential therapeutic 'mechanism of action' but that would need to be validated and tested in well-designed, robust clinical trials before any meaningful clinical conclusions can be drawn," he said.
That would include pre-registering clinical protocols and analysis methods, publishing in open access journals, double-blind placebo controlled trials, and strict, independent peer review by the clinical academic community, said Albertyn.
A turning tide
The problem is that without sufficient funding and further research, there is too little knowledge about cannabinoids — whether it's positive or negative research results — some say we just won't know until we do the research.
"But there is ENORMOUS interest now," said Kovalchuk in his email. And that's his emphasis. "The tide is coming."
While he and his co-authors say even their most effective extracts require large-scale validation, they say they may be a "safe addition" to the treatment of COVID-19. An addition, mind, alongside other treatments.
So, large-scale verification pending, medicinal cannabis could be developed into "easy-to-use preventative treatments," such as a mouthwash or a throat gargle in both clinical and home use.
Reposted with permission from Deutsche Welle.
- Mushrooms as Medicine? Psychedelics May Be Next Breakthrough ... ›
- What Is CBD Water, and Should You Drink It? - EcoWatch ›
- These California Nuns Grow Medical Marijuana, But Their City ... ›
- Moderna Announces Promising Coronavirus Vaccine Trials - EcoWatch ›
- Best CBD Oils of 2020: Reviews & Buying Guide - EcoWatch ›
- Singapore Will Plant One Million Trees by 2030 - EcoWatch ›
- Australia to Build the World's Largest Solar Farm to Power Singapore ›
- Giant Water Battery Cuts University's Energy Costs by $100 Million ... ›
EcoWatch Daily Newsletter
By Tara Lohan
In 1999 a cheering crowd watched as a backhoe breached a hydroelectric dam on Maine's Kennebec River. The effort to help restore native fish populations and the river's health was hailed as a success and ignited a nationwide movement that spurred 1,200 dam removals in two decades.
Transmission lines from the Churchill Falls generating station in Labrador. Douglas Spott / CC BY-NC 2.0
Atlantic sturgeon were brought to the brink of extension in the 20th century and are now are listed as an endangered species. NOAA
Near Happy Valley-Goose Bay on the Churchill (Grand) River downstream from Muskrat Falls. Douglas Sprott / CC BY-NC 2.0
Construction of the Site C dam in British Columbia in 2017. Jason Woodhead / CC BY 2.0
The Block Island Wind Farm off the coast of Rhode Island is the first U.S. offshore wind farm. Dennis Schroeder / NREL / CC BY-NC-ND 2.0
We pet owners know how much you love your pooch. It's your best friend. It gives you pure happiness and comfort when you're together. But there are times that dogs can be very challenging, especially if they are suffering from a certain ailment. As a dog owner, all you want to do is ease whatever pain or discomfort your best friend is feeling.
The excess carbon dioxide emitted by human activity since the start of the industrial revolution has already raised the Earth's temperature by more than one degree Celsius, increased the risk of extreme hurricanes and wildfires and killed off more than half of the corals in the Great Barrier Reef. But geologic history shows that the impacts of greenhouse gases could be much worse.
- Earth Is Hurtling Towards a Catastrophe Worse Than the Dinosaur ... ›
- Are We Doomed If We Don't Curb Carbon Emissions by 2030 ... ›
- Humans Release 40 to 100x More CO2 Than Volcanoes, Major ... ›
By Teri Schultz
Europe is in a panic over the second wave of COVID-19, with infection rates sky-rocketing and GDP plummeting. Belgium has just announced it will no longer test asymptomatic people, even if they've been in contact with someone who has the disease, because the backlog in processing is overwhelming. Other European countries are also struggling to keep up testing and tracing.
Meanwhile in a small cabin in Helsinki airport, for his preferred payment of a morsel of cat food, rescue dog Kossi needs just a few seconds to tell whether someone has coronavirus.